Study Evaluating Prevenar in High-Risk Children

Completed

• Conditions: Pneumococcal Disease

• Registration Number: NCT00234338
• Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer

Brief Summary

The purpose of this study is to estimate the local and systemic tolerability of Prevenar in children ages 2 to 5 years old in usual care settings.

Detailed Description

Not available

Study Timeline

• Study Start: 2005-10
• Study First Submitted: 2005-10-04
• Study First Submitted QC: 2005-10-05
• Study First Posted: 2005-10-06
• Study Completion: 2007-04
• Status Verified: 2007-12
• Last Update Submitted: 2007-12-07
• Last Update Posted: 2007-12-10

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 5000

Inclusion Criteria

• High-risk children ages 2 to 5 years old

Exclusion criteria:

• Prior administration of Prevenar
• Prior and/or concurrent administration of 23 vPs vaccine

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified